GLP-1s may improve outcomes in patients with PAD, diabetes

Дата публикации: 08-07-2026 14:48:04

GLP-1s may prevent adverse outcomes in patients with peripheral artery disease and diabetes, according to data published in the Journal of the American Heart Association.Researchers reported that GLP-1 receptor agonist use among patients with PAD and diabetes was associated with lower risk for mortality, hospitalization, revascularization and amputation compared with those prescribed metformin.“Obesity and PAD, including chronic limb-threatening ischemia, are linked to increased inflammation, poor blood vessel function, insulin resistance, oxidative stress and faster hardening of the

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	GLP-1s may lower risk for death, heart events among people with hidradenitis suppurativa	5	7	08-07-2026
2	GLP-1s for diabetes may increase risk for psoriatic disease	0	8.45	28-07-2026
3	New GLP-1 diabetes pill delivers major weight loss and blood sugar control	0	6.91	15-06-2026
4	Eli Lilly's Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity	7	8	31-07-2025
5	Different GLP-1 therapies could be tailored to patients' individual metabolic needs	0	7.25	27-07-2026
6	SGLT2 and GLP-1 medications unlock new potential in CKM care	2	6	09-07-2026
7	People On GLP-1s Like Ozempic And Zepbound Are Sharing The Surprise Benefits They Never Saw Coming, And Some Of These Genuinely Surprised Me	0	10.41	24-07-2026
8	Beyond the Jab: The Surprising New Frontiers of GLP-1 Therapy	0	14.13	24-07-2026
9	Most websites prescribe GLP-1s without clinician visit	0	7	09-07-2026
10	Регистрация Войти 14 часов назадИсточник: Hi-Tech MailНаука «Оземпик» замедляет биологическое старение: ...	5	7	17-07-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 5. Информативность: 7. Источник: www.healio.com.